Experts show wide range of opinion on PCa prevention trial
Seattle-Leading U.S. prostate cancer thought leaders are expressingwidely divergent opinions on the recent announcement of a 25% reductionin prostate cancer incidence in men treated with finasteride (Proscar),according to interviews conducted by Urology Times. Whereas some expertssee the finding as the beginning of a new era in prostate cancer prevention,others say that more data are needed before urologists can confidently applythe finding to clinical practice.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.